Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results
| Autor: | Marcus Maurer, Paolo Tassinari, Luis Felipe Ensina, Chia-Yu Chu, Xavier Jaumont, Ana Giménez-Arnau |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
PRO
CIndU chronic inducible urticaria Urticaria Asia-Pacific and the Middle East Omalizumab 0302 clinical medicine Quality of life LaCAN Immunology and Allergy Central and Latin America DLQI 030223 otorhinolaryngology Patient-reported outcome UAS7 AMAC Asia-Pacific and the Middle East AMAC PRO patient-reported outcome CU chronic urticaria Dermatology Life Quality Index Chronic urticaria Chronic spontaneous urticaria AWARE A Worldwide Antihistamine-Refractory Chronic Urticaria patient Evaluation DLQI dermatology life quality index Patient evaluation medicine.symptom CU medicine.drug Pulmonary and Respiratory Medicine lcsh:Immunologic diseases. Allergy QoL medicine.medical_specialty Chronic inducible urticaria 7-day urticaria activity score Immunology Dermatology Article UAS7 7-day urticaria activity score CIndU 03 medical and health sciences Internal medicine medicine CSU Standard deviation Angioedema SD business.industry CSU chronic spontaneous urticaria A Worldwide Antihistamine-Refractory Chronic Urticaria patient Evaluation LaCAN Central and Latin America QoL quality of life Dermatology life quality index 030228 respiratory system Multicenter study Quality-of-life business SD standard deviation lcsh:RC581-607 AWARE |
| Zdroj: | World Allergy Organization Journal, Vol 13, Iss 9, Pp 100460-(2020) The World Allergy Organization Journal |
| ISSN: | 1939-4551 |
| Popis: | Background A Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient Evaluation (AWARE) is a non-interventional, multicenter study including patients from Europe, Central and Latin America, Asia-Pacific, and the Middle East. AWARE describes real-world evidence for CU, including clinical characteristics, treatment patterns and the impact on quality of life. Methods Over the 2-year study, therapy changes, angioedema occurrence, and patient-reported outcomes (PROs) were recorded over 9 visits, including dermatology life quality index (DLQI) and 7-day urticaria activity score (UAS7). Data were stratified into subgroups: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or CSU + CIndU. Results Out of 4838 patients analyzed, 9.9% were receiving no treatment for their CU symptoms at baseline, and 20.4% were receiving first-line non-sedating H1-antihistamine at approved doses. The predominant baseline therapy was up-dosed non-sedating H1-antihistamines (25.5%). By Visit 2, omalizumab was the overall most commonly used therapy (29.6%), increasing to 30.1% by the end of the study. Baseline DLQI scores for patients with CSU, CIndU and CSU + CIndU were 8.3, 7.6 and 9.1, respectively; scores decreased over the study for CSU and CSU + CIndU patients, but fluctuated for CIndU patients. Baseline angioedema occurrence was higher in CSU and CSU + CIndU patients, reported in 45.4% and 45.5% of patients, respectively, compared to 17.0% in CIndU patients. By the final visit, angioedema had decreased to 11.9% and 11.2% for CSU and CSU + CIndU, respectively, and 9.6% for CIndU. Conclusion CU patients are undertreated at baseline; after entering the AWARE study, more patients received appropriate treatment. However, over two thirds are not escalated to third-line treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|